Provenance du réseau au premier degré de Bruce Close
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 18 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Bruce Close via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
Metamark Genetics, Inc.
 Metamark Genetics, Inc. Medical/Nursing ServicesHealth Services Metamark Genetics, Inc. provides molecular diagnostics services. It develops prognostic and predictive diagnostic tests that will enable personalized treatment planning for cancer patients. It transforms cancer diagnosis and treatment by developing pioneering diagnostic products based on its prognosis determinants platform. The company was founded by Kenneth E. Weg, Raju S. Kucherlapati, David Rimm, Lynda Chin and Ronald A. DePinho in November 2007 and is headquartered in Waltham, MA. | Medical/Nursing Services | Chief Operating Officer Corporate Officer/Principal | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree | |
| DYAX CORP. | Pharmaceuticals: Major | Chief Administrative Officer | |
| 89BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
| DAY ONE BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| ACHILLES THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
| CONNECT BIOPHARMA HOLDINGS LIMITED | Pharmaceuticals: Major | Director/Board Member | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| ITEOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Canbridge Pharmaceuticals, Inc. (United States)
 Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Biotechnology | Director/Board Member | |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor | |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
| CANBRIDGE PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree | |
| College of the Holy Cross (Massachusetts) | College/University | Undergraduate Degree | |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Investment Managers | Analyst-Equity | |
| University of Strasbourg | College/University | Doctorate Degree | |
| EMD Serono Research & Development Institute, Inc. | Corporate Officer/Principal | ||
| AGENUS INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Terremoto Biosciences, Inc.
 Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
| POSEIDA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Odyssey Therapeutics, Inc.
 Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | Packaged Software | Director/Board Member | |
| PMV PHARMACEUTICALS, INC. | Miscellaneous Commercial Services | Director/Board Member | |
89Bio Ltd.
 89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Pharmaceuticals: Major | Director/Board Member | |
| MINERALYS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| University of Lund | College/University | Doctorate Degree | |
| DYNAVAX TECHNOLOGIES CORPORATION | Biotechnology | Corporate Officer/Principal | |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| ZENTALIS PHARMACEUTICALS, INC. | Biotechnology | Investor Relations Contact | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal | |
| Kellogg School of Management | College/University | Masters Business Admin | |
| University of Illinois | College/University | Doctorate Degree | |
| TURG POIN | Pharmaceuticals: Major | Investor Relations Contact | |
Vesselon, Inc.
 Vesselon, Inc. Medical SpecialtiesHealth Technology Vesselon, Inc. develops a portable ultrasound medical device for treating neurodegenerative diseases and brain & ischemic strokes. It commercializes a drug delivery platform that combines ultrasound and microbubbles to deliver the drugs across tissue barriers directly into a target without the need to modify the drug through a process, microbubble assisted sono-therapy. The company was founded by Clayton T. Larsen and Rhodemann Li in 2012 and is headquartered in Norwalk, CT. | Medical Specialties | Director/Board Member | |
| ALAUNOS THERAPEUTICS, INC. | Biotechnology | Investor Relations Contact | |
| ZAI LAB LIMITED | Biotechnology | Corporate Officer/Principal | |
Suzhou Connect Biopharma Co. Ltd.
 Suzhou Connect Biopharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China. | Pharmaceuticals: Major | Director/Board Member | |
| BUTTERFLY NETWORK, INC. | Medical Specialties | General Counsel | |
| Boston College | College/University | Undergraduate Degree | |
| Boston College Law School | College/University | Graduate Degree | |
Fidelity Investments, Inc.
 Fidelity Investments, Inc. Financial ConglomeratesFinance Fidelity Investments, Inc. operates as a financial services company. The company is headquartered in Boston, MA. | Financial Conglomerates | General Counsel | |
Ropes & Gray LLP
 Ropes & Gray LLP Miscellaneous Commercial ServicesCommercial Services Ropes & Gray LLP provides legal and private equity services. Its practice areas include asset management, banking, business and commercial litigation, business restructuring, capital markets and corporate governance and compliance. The company was founded in 1865 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| THE CANNABIST COMPANY HOLDINGS INC. | Pharmaceuticals: Other | General Counsel | |
| KINIKSA PHARMACEUTICALS, LTD. | Pharmaceuticals: Major | Founder | |
Oncomyx Therapeutics, Inc.
 Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Packaged Software | Chairman | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| IMMUNOMEDICS, INC. | Biotechnology | Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 40 |
| Chine | 4 |
| Royaume-Uni | 3 |
| France | 3 |
| Danemark | 2 |
Sectorielle
| Health Technology | 31 |
| Consumer Services | 10 |
| Finance | 5 |
| Technology Services | 4 |
| Commercial Services | 3 |
Opérationnelle
| Director/Board Member | 42 |
| Corporate Officer/Principal | 31 |
| Independent Dir/Board Member | 21 |
| Doctorate Degree | 9 |
| Chief Tech/Sci/R&D Officer | 9 |
Relations les plus connectées
| Insiders | |
|---|---|
| Ivana Magovcevic-Liebisch | 18 |
| Derek DiRocco | 17 |
| Charles Baum | 12 |
| Michael Tomsicek | 12 |
| Adam Levy | 8 |
| Mary Miller | 8 |
| Eric Devroe | 8 |
| Peter Blume-Jensen | 8 |
| Sharon Shacham | 5 |
| Jean-Marie Cuillerot | 4 |
| Rasmus Holm-Jorgensen | 4 |
| Erick Gamelin | 4 |
| Karl Hsu | 2 |
| Kristina Masson | 2 |
| Praveen Marapaka | 1 |
- Bourse
- Insiders
- Bruce Close
- Connexions Sociétés
